Medicus Pharma Seeks FDA Meeting for 200µg Cohort After Expert-Endorsed Phase 2 Data
Independent dermatology expert Dr. Babar Rao endorsed Medicus Pharma’s Skinject Phase 2 topline data, which showed clinical activity across device-only and two doxorubicin arms. The 200µg doxorubicin cohort emerged as the lead candidate, and the company plans an end-of-Phase 2 FDA meeting under the 505(b)(2) pathway.
1. Independent Validation and Phase 2 Data
Medicus Pharma completed a three-arm Phase 2 study of its Skinject microneedle platform in non-melanoma skin disease, including device-only and 100µg and 200µg doxorubicin cohorts. Topline results showed clinical activity across all arms, and leading dermatology expert Dr. Babar Rao endorsed the safety and efficacy signals during a recent update call. This external validation adds credibility to the platform’s noninvasive approach.
2. Focus on 200µg Doxorubicin Cohort and Regulatory Strategy
Among the doxorubicin arms, the 200µg cohort delivered the most promising responses, prompting the company to center its regulatory dossier on this data set. Medicus Pharma intends to leverage the FDA’s 505(b)(2) pathway, which can reduce development timelines and costs by referencing existing chemotherapeutic data. This focused strategy is designed to streamline approval and support a clear commercialization plan.
3. Upcoming FDA Meeting as Next Catalyst
The company plans to initiate an end-of-Phase 2 meeting with the FDA to discuss the 200µg cohort’s data package. Successful feedback in this meeting could define pivotal trial design, regulatory requirements and potential launch timelines. Investors view this engagement as a key near-term catalyst that could significantly de-risk the development program.